Charles River Laboratories International Inc (CRL)
195.77
+1.58
(+0.81%)
USD |
NYSE |
Nov 22, 16:00
195.80
+0.03
(+0.02%)
After-Hours: 20:00
Charles River Laboratories International Revenue (Quarterly): 1.010B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.010B |
| June 30, 2024 | 1.026B |
| March 31, 2024 | 1.012B |
| December 31, 2023 | 1.013B |
| September 30, 2023 | 1.027B |
| June 30, 2023 | 1.060B |
| March 31, 2023 | 1.029B |
| December 31, 2022 | 1.100B |
| September 30, 2022 | 989.16M |
| June 30, 2022 | 973.13M |
| March 31, 2022 | 913.93M |
| December 31, 2021 | 905.05M |
| September 30, 2021 | 895.94M |
| June 30, 2021 | 914.61M |
| March 31, 2021 | 824.57M |
| December 31, 2020 | 790.99M |
| September 30, 2020 | 743.30M |
| June 30, 2020 | 682.58M |
| March 31, 2020 | 707.06M |
| December 31, 2019 | 691.14M |
| September 30, 2019 | 667.95M |
| June 30, 2019 | 657.57M |
| March 31, 2019 | 604.57M |
| December 31, 2018 | 601.53M |
| September 30, 2018 | 585.30M |
| Date | Value |
|---|---|
| June 30, 2018 | 585.30M |
| March 31, 2018 | 493.97M |
| December 31, 2017 | 478.48M |
| September 30, 2017 | 464.23M |
| June 30, 2017 | 469.13M |
| March 31, 2017 | 445.76M |
| December 31, 2016 | 466.79M |
| September 30, 2016 | 425.72M |
| June 30, 2016 | 434.06M |
| March 31, 2016 | 354.87M |
| December 31, 2015 | 353.85M |
| September 30, 2015 | 349.46M |
| June 30, 2015 | 339.57M |
| March 31, 2015 | 320.41M |
| December 31, 2014 | 329.55M |
| September 30, 2014 | 327.57M |
| June 30, 2014 | 341.18M |
| March 31, 2014 | 299.37M |
| December 31, 2013 | 289.23M |
| September 30, 2013 | 292.13M |
| June 30, 2013 | 292.93M |
| March 31, 2013 | 291.24M |
| December 31, 2012 | 280.14M |
| September 30, 2012 | 278.69M |
| June 30, 2012 | 284.72M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
682.58M
Minimum
Jun 2020
1.100B
Maximum
Dec 2022
915.41M
Average
943.87M
Median
Revenue (Quarterly) Benchmarks
| Boston Scientific Corp | 4.209B |
| CVS Health Corp | 95.43B |
| Arbutus Biopharma Corp | 1.339M |
| FibroBiologics Inc | -- |
| Biomarin Pharmaceutical Inc | 745.74M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 68.68M |
| Total Expenses (Quarterly) | 892.36M |
| EPS Diluted (Quarterly) | 1.33 |
| Enterprise Value | 12.17B |
| Gross Profit Margin (Quarterly) | 34.56% |
| Profit Margin (Quarterly) | 6.80% |
| Earnings Yield | 4.09% |
| Operating Earnings Yield | 5.22% |
| Normalized Earnings Yield | 4.092 |